Furthermore, the potential benefit of GM-CSF as a pulmonary therapy has been shown directly in several other animal models in which GM-CSF treatment was able to both protect against and treat bacterial and viral pneumonias52–61, which, like COVID-19, induce a cytokine storm that can lead to respiratory distress and multi-organ failure. This evidence concerns the gene CSF2 and COVID-19.